Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gene Polymorphisms in Cyclophosphamide Metabolism Pathway,Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer

15 Dec 2010

Abstract excerpt

PURPOSE: There are no established genetic markers for prediction of outcomes after cyclophosphamide (CP)-containing adjuvant therapy for breast cancer. In an ancillary study to a SWOG (Southwest Oncology Group) trial (S8897), we investigated functional polymorphisms in 4 genes in CP pharmacokinetic pathways in relation to hematologic toxicity and disease-free survival (DFS). EXPERIMENTAL DESIGN: Germline DNA was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Transport and Resistance Mechanisms
Share to Estrogen and related hormone effects
Share to Glutathione Transferases and Polymorphisms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21169260
DOI: 10.1158/1078-0432.ccr-10-0281

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gene Polymorphisms in Cyclophosphamide Metabolism Pathway,Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast CancerPMID 21169260Read ↗

Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.Semantic proximity Read ↗

Effects of CYP2B6 genetic polymorphisms in patients receiving cyclophosphamide combination chemotherapy for breast cancer.Semantic proximity Read ↗

Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients.Semantic proximity Read ↗

Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer.Semantic proximity Read ↗

Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel.Semantic proximity Read ↗

Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors.Semantic proximity Read ↗

Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC).Semantic proximity Read ↗

Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer.Semantic proximity Read ↗

Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patientsSemantic proximity Read ↗

Gemcitabine and platinum pathway pharmacogenetics in Asian breast cancer patients.Semantic proximity Read ↗

Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients.Semantic proximity Read ↗

Lack of association of CYP2B6 pharmacogenetics with cyclophosphamide toxicity in patients with cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.